Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Queensland Health
Argus Health
McKinsey
US Army
Cipla
Fish and Richardson
Cerilliant

Generated: May 22, 2018

DrugPatentWatch Database Preview

Claims for Patent: 7,459,151

« Back to Dashboard

Summary for Patent: 7,459,151
Title:Phosphate-binding polymers for oral administration
Abstract:Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
Inventor(s): Holmes-Farley; Stephen Randall (Arlington, MA), Mandeville, III; W. Harry (Lynnfield, MA), Whitesides; George M. (Newton, MA)
Assignee: Genzyme Corporation (Cambridge, MA)
Application Number:11/295,159
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,459,151
Patent Claims: 1. A method for removing phosphate from a patient in need thereof comprising orally administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising a crosslinked, water insoluble polyallylamine copolymer wherein said crosslinked, water insoluble polyallylamine copolymer consists of a crosslinking agent and repeat units represented by the following structural formulae: ##STR00028## wherein n is an integer, and X.sup.- represents a negatively charged counterion.

2. The method of claim 1 wherein said polyallylamine copolymer is crosslinked with an epichlorohydrin crosslinking agent.

3. The method of claim 1 wherein the amount of said crosslinking agent is about 2% to about 20% by weight of the polyallylamine copolymer.

4. The method of claim 2 wherein the amount of said crosslinking agent is about 2% to about 20% by weight of the polyallylamine copolymer.

5. The method of claim 1 wherein said pharmaceutical composition further comprises one or more carriers.

6. The method of claim 2 wherein said pharmaceutical composition further comprises one or more carriers.

7. The method of claim 4 wherein said pharmaceutical composition further comprises one or more carriers.

8. The method of claim 1 wherein X.sup.- represents chloride.

9. The method of claim 4 wherein X.sup.- represents chloride.

10. The method of claim 6 wherein X.sup.- represents chloride.

11. A method of decreasing the serum phosphate level of a patient in need thereof comprising orally administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising a crosslinked, water insoluble polyallylamine copolymer wherein said crosslinked, water insoluble polyallylamine copolymer consists of a crosslinking agent and repeat units represented by the following structural formulae: ##STR00029## wherein n is an integer, and X.sup.- represents a negatively charged counterion.

12. The method of claim 11 wherein said polyallylamine copolymer is crosslinked with an epichlorohydrin crosslinking agent.

13. The method of claim 11 wherein the amount of said crosslinking agent is about 2% to about 20% by weight of the polymer.

14. The method of claim 12 wherein the amount of said crosslinking agent is about 2% to about 20% by weight of the polymer.

15. The method of claim 11 wherein said pharmaceutical composition further comprises one or more carriers.

16. The method of claim 12 wherein said pharmaceutical composition further comprises one or more carriers.

17. The method of claim 14 wherein said pharmaceutical composition further comprises one or more carriers.

18. The method of claim 11 wherein X.sup.- represents chloride.

19. The method of claim 14 wherein X.sup.- represents chloride.

20. The method of claim 16 wherein X.sup.- represents chloride.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Julphar
Medtronic
Accenture
Boehringer Ingelheim
US Department of Justice
Queensland Health
Merck
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.